Subjects:
Free Research Articles
Page 2755: In Figure 1A, the label “Overall Survival by HMA treatment: Median Months (95% CI)” should be “Overall Survival: Median Months (95% CI).” In Figure 1C, the label “Overall Survival by Treatment (VEN + LDAC): Median Months (95% CI)” should be “Overall Survival by Prior HMA Exposure (VEN + LDAC): Median Months (95% CI).” In the key to the graph curves in Figure 1F, “NPMI” should be “NPM1.” The corrected Figure 1 is shown below.
Figure 1
Survival outcomes and response in patients treated with VEN compared with PBO. (A) Kaplan-Meier OS curves of all patients. Number of patients at risk for each time is shown below and separated by treatment arms. (B) Kaplan-Meier duration of response curves in patients treated with VEN + LDAC. Number of patients at risk for each time is shown below and separated by response. (C) Kaplan-Meier OS by prior HMA treatment curves in patients treated with VEN + LDAC. Number of patients at risk for each time is shown below and separated by prior HMA treatment. (D) Kaplan-Meier OS by remission status curves in patients treated with VEN + LDAC. Number of patients at risk for each time is shown below and separated by response. (E) Kaplan-Meier OS by AML type curves in patients treated with VEN + LDAC. Number of patients at risk for each time is shown below and separated by AML type. (F) Kaplan-Meier OS by mutational status curves in patients treated with VEN + LDAC. Number of patients at risk for each time is shown below and separated by mutational status. AML, acute myeloid leukemia; CR, complete remission; CRi, complete remission with incomplete blood count recovery; DOR, duration of remission; HMA, hypomethylating agent; LDAC, low dose cytarabine; PBO, placebo; VEN, venetoclax.
View largeDownload PPT

Survival outcomes and response in patients treated with VEN compared with PBO. (A) Kaplan-Meier OS curves of all patients. Number of patients at risk for each time is shown below and separated by treatment arms. (B) Kaplan-Meier duration of response curves in patients treated with VEN + LDAC. Number of patients at risk for each time is shown below and separated by response. (C) Kaplan-Meier OS by prior HMA treatment curves in patients treated with VEN + LDAC. Number of patients at risk for each time is shown below and separated by prior HMA treatment. (D) Kaplan-Meier OS by remission status curves in patients treated with VEN + LDAC. Number of patients at risk for each time is shown below and separated by response. (E) Kaplan-Meier OS by AML type curves in patients treated with VEN + LDAC. Number of patients at risk for each time is shown below and separated by AML type. (F) Kaplan-Meier OS by mutational status curves in patients treated with VEN + LDAC. Number of patients at risk for each time is shown below and separated by mutational status. AML, acute myeloid leukemia; CR, complete remission; CRi, complete remission with incomplete blood count recovery; DOR, duration of remission; HMA, hypomethylating agent; LDAC, low dose cytarabine; PBO, placebo; VEN, venetoclax.

Figure 1
Survival outcomes and response in patients treated with VEN compared with PBO. (A) Kaplan-Meier OS curves of all patients. Number of patients at risk for each time is shown below and separated by treatment arms. (B) Kaplan-Meier duration of response curves in patients treated with VEN + LDAC. Number of patients at risk for each time is shown below and separated by response. (C) Kaplan-Meier OS by prior HMA treatment curves in patients treated with VEN + LDAC. Number of patients at risk for each time is shown below and separated by prior HMA treatment. (D) Kaplan-Meier OS by remission status curves in patients treated with VEN + LDAC. Number of patients at risk for each time is shown below and separated by response. (E) Kaplan-Meier OS by AML type curves in patients treated with VEN + LDAC. Number of patients at risk for each time is shown below and separated by AML type. (F) Kaplan-Meier OS by mutational status curves in patients treated with VEN + LDAC. Number of patients at risk for each time is shown below and separated by mutational status. AML, acute myeloid leukemia; CR, complete remission; CRi, complete remission with incomplete blood count recovery; DOR, duration of remission; HMA, hypomethylating agent; LDAC, low dose cytarabine; PBO, placebo; VEN, venetoclax.
View largeDownload PPT

Survival outcomes and response in patients treated with VEN compared with PBO. (A) Kaplan-Meier OS curves of all patients. Number of patients at risk for each time is shown below and separated by treatment arms. (B) Kaplan-Meier duration of response curves in patients treated with VEN + LDAC. Number of patients at risk for each time is shown below and separated by response. (C) Kaplan-Meier OS by prior HMA treatment curves in patients treated with VEN + LDAC. Number of patients at risk for each time is shown below and separated by prior HMA treatment. (D) Kaplan-Meier OS by remission status curves in patients treated with VEN + LDAC. Number of patients at risk for each time is shown below and separated by response. (E) Kaplan-Meier OS by AML type curves in patients treated with VEN + LDAC. Number of patients at risk for each time is shown below and separated by AML type. (F) Kaplan-Meier OS by mutational status curves in patients treated with VEN + LDAC. Number of patients at risk for each time is shown below and separated by mutational status. AML, acute myeloid leukemia; CR, complete remission; CRi, complete remission with incomplete blood count recovery; DOR, duration of remission; HMA, hypomethylating agent; LDAC, low dose cytarabine; PBO, placebo; VEN, venetoclax.

Close modal
© 2023 by The American Society of Hematology
2023
Sign in via your Institution